Trial Profile
A phase Ib trial of ZEN 3694 in combination with enzalutemide as second-line therapy in metastatic castrate resistent prostate cancer patients
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Dec 2016
Price :
$35
*
At a glance
- Drugs ZEN 3694 (Primary) ; Enzalutamide
- Indications Prostate cancer
- Focus Adverse reactions; Proof of concept
- Sponsors Zenith Epigenetics
- 21 Dec 2016 New trial record